8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Cost-effectiveness analyses from the FREEDOM trial of denosumab for postmenopausal osteoporosis: cost per QALY, payer coverage, list-price vs net-price dynamics, and patient-level value calculations.
Deep dive into the FREEDOM trial extension: 10-year denosumab durability data, rebound vertebral fractures after discontinuation, and long-term safety signals including ONJ and atypical femoral fractures.
A deep dive into the FREEDOM trial's primary and secondary endpoint data for denosumab in postmenopausal osteoporosis, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of fracture reduction.
A deep dive into the FREEDOM trial's pre-specified and post-hoc subgroup analyses, examining how age, BMI, baseline T-score, fracture history, and bone turnover markers influenced denosumab's efficacy in postmenopausal osteoporosis.
A deep-dive into the FREEDOM trial (2009) that proved denosumab reduces vertebral fractures by 68% in postmenopausal women with osteoporosis, establishing it as a first-line therapy.
A clinical deep-dive into the enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest concerns surrounding the FREEDOM denosumab trial.
A detailed methodology breakdown of the FREEDOM trial (denosumab vs placebo for postmenopausal osteoporosis), covering randomization, blinding, endpoint definitions, statistical design, and how each choice shapes clinical interpretation.
How the FREEDOM trial reshaped osteoporosis treatment guidelines, shifted prescribing patterns for denosumab, and what clinicians should consider for patients outside the original study population.